13.80
13.80 (0%)
As of Feb 14, 2025
Hutchmed [HCM]
Source:
Company Overview
Hutchmed is a global commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of patients with cancer and immunological diseases.
| Country | Canada |
| Headquarters | hong kong |
| Phone Number | 852-2121-3888 |
| Industry | manufacturing |
| CEO | Weiguo Su |
| Website | www.hutch-med.com/shareholder-information. |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $630.2 |
| Operating Profit | $-43.7 |
| Net Income | $38.2 |
| Net Cash | $-126.2 |
Profit Ratios
| Gross Margin | $979.1 |
| Operating Margin | -6.9 |
| Profit as % of Revenues | 2,565.1% |
| Profit as % of Assets | 3% |
| Profit as % of Stockholder Equity | 5% |
Management Effectiveness
| Return on Equity | 5% |
| Return on Assets | 3% |
| Turnover Ratio | 49.4% |
| EBITA | $-43.7 |
Balance Sheet and Cash Flow Measures
| Total Assets | $1,274.2 |
| Total Liabilities | $502.3 |
| Operating Cash Flow | $0.5 |
| Investing Cash Flow | $-96.1 |
| Financing Cash Flow | $-30.7 |
